Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867924 | 1.00 | MGLL (0.58) | MGLLGPR119NAMPTCYP11B2DDB1 | |
| SCHEMBL23867885 | 0.83 | MGLL (0.58) | MGLLGPR119NAMPTACACB | |
| SCHEMBL29469963 | 0.83 | MGLL (0.58) | MGLLGPR119NAMPTACACB | |
| SCHEMBL23868004 | 0.81 | MGLL (0.58) | MGLLGPR119NAMPTCYP11B2ACACB | |
| SCHEMBL29324641 | 0.80 | GRM5 (0.47) | MGLLGPR119NAMPTCYP11B2ACACB | |
| SCHEMBL23867921 | 0.78 | MGLL (0.55) | MGLLGPR119NAMPTCYP11B2ACACB | |
| SCHEMBL30104744 | 0.78 | MGLL (0.55) | MGLLGPR119NAMPTCYP11B2ACACB | |
| SCHEMBL23867882 | 0.78 | MGLL (0.58) | MGLLGPR119NAMPTACACB | |
| SCHEMBL23867946 | 0.78 | MGLL (0.61) | MGLL | |
| SCHEMBL24350442 | 0.77 | MGLL (0.53) | MGLLNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362153-B | Azaspiro compounds as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-4126852-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| US-11505546-B2 | Azaspirocycles as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-22 | — | — | US | disclosed |
| CN-115362153-A | Aza spiro rings as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220081428-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | MGLL 1/4885GPR119 254/4885NAMPT 1908/4885 |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | MGLL, LPAR1, LPL | MGLL 1/4885GPR119 273/4885NAMPT 2019/4885 |
| US-20220081428-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPAR1, LPL | MGLL 1/4885GPR119 273/4885NAMPT 2019/4885 |
| US-11505546-B2 | Azaspirocycles as monoacylglycerol lipase modulators | MGLL, LPAR1, LPL | MGLL 1/4885GPR119 273/4885NAMPT 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.